Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01719432 · ClinicalTrials.gov registry record
Effect of Body Mass on Filgrastim Pharmacokinetics
A clinical trial of Neutropenia and Hematological Malignancy, sponsored by Aaron Cumpston, PharmD, BCOP.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT01719432: Completed study of Neutropenia and Hematological Malignancy, sponsored by Aaron Cumpston, PharmD, BCOP.
NCT01719432 is a study of Neutropenia and Hematological Malignancy that has completed, run by Aaron Cumpston, PharmD, BCOP. The registered enrollment target is 30 participants, below the 75-participant average among 12 other Neutropenia trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01719432, a study of Neutropenia and Hematological Malignancy, has completed, sponsored by Aaron Cumpston, PharmD, BCOP.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan. Patients in this study will have blood draws once before they take Neupogen and 6 times after they take the Neuopen (for a total of 24 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 5-6 tablespoons of blood will be drawn for this study. 15 obese patients and 15 matched, non-obese patients will be enrolled into this study.
Conditions Studied
Study Locations (1)
West Virginia
- West Virginia University Mary Babb Randolph Cancer Center - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-12-05 |
| Est. Completion | 2020-12 |
What the finished NCT01719432 record still lists
NCT01719432 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 75-participant average among 12 other Neutropenia trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Neutropenia appearing as the primary indexed condition, and to 0 interventions.
NCT01719432 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT01719432 about?
NCT01719432 is a clinical study titled "Effect of Body Mass on Filgrastim Pharmacokinetics". Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher body weights affect drug exposure. The information gathered from this st...
What is the current status of trial NCT01719432?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2012-12-05. Estimated completion is 2020-12.
What conditions does trial NCT01719432 study?
This clinical trial studies the following conditions: Neutropenia, Hematological Malignancy.
Who is sponsoring clinical trial NCT01719432?
This trial is sponsored by Aaron Cumpston, PharmD, BCOP, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01719432 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01719432's enrollment target sits among peer trials
30 8th of 12 higher than 5 of 12 other Neutropenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neutropenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
RECRUITING · Phase 1
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
RECRUITING · Phase 3
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Serial Blood Count Study
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI